* EMA: PRAC STARTS REVIEW OF TOPIRAMATE USE IN PREGNANCY AND WOMEN OF CHILDBEARING POTENTIAL: 02/09/2022
* EMA-COMMITTEE WILL LOOK IN PARTICULAR AT CURRENT RISK MINIMISATION MEASURES,CONSIDER NEED FOR ADDITIONAL MEASURES TO MINIMISE RISKS OF TOPIRAMATE USE * EMA: WHILE THE REVIEW IS ONGOING, TOPIRAMATE SHOULD CONTINUE TO BE USED ACCORDING TO THE AUTHORISED PRODUCT INFORMATION Source text for Eikon: Further company coverage: [ ]
(This story was not edited by Devdiscourse staff. It is generated automatically from a syndicated feed.
